[1]
Ring J, Kramer U, Shafer T, and Behrendt H. Why are allergies increasing? Curr Opin Immunol 2001; 13: 701-8.
[2]
Martins P, Jesus J, Santos S, et al. Heterocyclic anticancer compounds: recent advances and the paradigm shift towards the use of nanomedicine’s tool box. Molecules 2015; 20: 16852-91.
[3]
Godhani DR, Jogel AA, Sanghani AM and, Mehta JP. Synthesis and biological screening of 1,2,4-triazole derivatives. Ind J Chem 2015; 54B: 556-64.
[4]
Simons FE and, Simons KJ. Histamine and H1-antihistamines: Celebrating a century of progress. J Allergy Clin Immunol 2011; 128: 1139-50.
[5]
Gushchin IS. Inverse agonists of H1 receptors as promising antiallergy agents. Pharm Chem J 2010; 44: 1-6.
[6]
Baroody FM, and Naclerio RM. Antiallergic effects of H1-receptor antagonists. Allergy 2000; 55: 17-27.
[7]
Chen MD, Lu SJ, Yuan GP, Yang SY, Du XL. Synthesis and antibacterial activity of some heterocyclic beta-enamino ester derivatives with 1,2,3-triazole. Heterocyclic Comm 2000; 6: 421-6.
[8]
Sheremet EA, Tomanov RI, Trukhin EV, Berestovitskaya VM. Synthesis of 4-aryl-5-nitro-1,2,3-triazoles. Russ J Org Chem 2004; 40: 594-5.
[9]
Hafez HN, Abbas HA, El-Gazzar AR. Synthesis and evaluation of analgesic, anti-inflammatory and ulcerogenic activities of some triazolo- and 2-pyrazolyl-pyrido[2,3-d]-pyrimidines. Acta Pharm 2008; 58: 359-78.
[10]
Banu KM, Dinakar A, Ananthanarayanan C. Synthesis, characterization, antimicrobial studies and pharmacological screening of some substituted 1,2,3-triazoles. Indian J Pharm Sci 1999; 61: 202-5.
[11]
Guan LP, Jin QH, Tian GR, Chai KY, Quan ZS. Synthesis of some quinoline-2(1H)-one and 1,2,4-triazolo [4,3-a]quinoline derivatives as potent anticonvulsants. J Pharm Sci 2007; 10: 254-62.
[12]
Passannanti A, Diana P, Barraja P, Mingoia F, Lauria A, Cirrincione G. Pyrrolo[2,3-d][1,2,3]triazoles as potential antineoplastic agents. Heterocycles 1998; 48: 1229-35.
[13]
Gujjar R, Marwaha A, El Mazouni F, et al. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. J Med Chem 2009; 52: 1864-72.
[14]
Johns BA, Weatherhead JG, Allen SH, et al. The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors Part 1: Establishing the pharmacophore. Bioorg Med Chem Lett 2009; 19: 1802-6.
[15]
Manfredini S, Vicentini CB, Manfrini M, et al. Pyrazolo-triazoles as light activable DNA cleaving agents. Bioorg Med Chem 2000; 8: 2343-6.
[16]
Duran A, Dogan HN, Rollas S. Synthesis and preliminary anticancer activity of new 1,4-Dihydro-3-(3-hydroxy-2- naphthyl)-4-substituted-5H-1,2,4-triazoline-5-thiones. Farmaco 2002; 57: 559-64.
[17]
Sztanke K, Tuzimski T, Rzymowska J, et al. Synthesis, determination of the lipophilicity, anticancer and antimicrobial properties of some fused 1,2,4-triazole derivatives. Eur J Med Chem 2008; 43: 404-19.
[18]
Sadek B, Alisch R, Buschauer A, Elz S. Synthesis and dual histamine H1 and H2 receptor antagonist activity of cyanoguanidine derivatives. Molecules 2013; 18: 14186-202.
[19]
Elbayaa RY. Computer-aided design, synthesis and biological evaluation of 5- substituted aminomethylenepyrimidine-2,4,6-triones as H1 antihistaminic agents (Part2). Med Chem 2014; 10: 66-73.
[20]
Gobinath M, Subramanian N, Alagarsamy V. Design, synthesis and H1-antihistaminic activity of novel 1-substituted-4-(3-chlorophenyl)-[1,2,4] triazolo [4,3-a] quinazolin-5(4H)-ones. J Saudi Chem Soc 2015; 19(3): 282-6.
[21]
Shaikh MH, Subhedar DD, Nawale L, et al. 1,2,3-Triazole derivatives as antitubercular agents: synthesis, biological evaluation and molecular docking study. Med Chem Commun 2015; 6: 1104-16.
[22]
Sadeghpour H, Khabnadideh S, Zomorodian K, et al. Design, Synthesis, and Biological Activity of New Triazole and Nitro-Triazole Derivatives as Antifungal Agents. Molecules 2017; 22: 1150-61.
[23]
Loustaud-Ratti V, Debette-Gratien M, Jacques J, et al. Ribavirin: Past, present and future. World J Hepatol 2016; 8(2): 123-30.
[25]
Shimamura T, Shiroishi M, Weyand S, et al. Structure of the human histamine H1 receptor complex with doxepin. Nature 2011; 475: 65-70.
[26]
Lalitha P, Sivakamasundari S. Calculation of molecular lipophilicity and drug likeness for few heterocycles. Orient J Chem 2010; 26(1): 135-41.
[27]
Panchal II, Shah AP, Devgirkar A, et al. In silico analysis and molecular docking studies of novel 6,7-dihydropyrano[2,3-d]pyrimidin-5-one derivatives as Human Epidermal Growth Factor Receptor 2 (HER2) and Epidermal Growth Factor Receptor (EGFR) Inhibitors. Curr Cancer Ther Rev 2019; 15(3): 235-47.
[28]
Furniss BS, Hannaford AJ, Smith PW, and Tatchell AR. In Vogel’s text book of Practical Organic Chemistry. 5th Edn;. Longman Scientific & Technical 1989; p. 1077.
[29]
Furniss BS, Hannaford AJ, Smith PW, and Tatchell AR. In Vogel’s text book of Practical Organic Chemistry. 5th Edn;. Longman Scientific & Technical 1989; p. 1269.
[30]
Reid JR, and Heindel ND. Improved syntheses of 5-substituted-4-amino-3-mercapto-(4-H)-1,2,4-triazoles. J Het Chem 1976; 13: 925-6.
[31]
Dave TK, Purohit DH, Akbari JD and, Joshi HS. Synthesis and pharmacological study of thiazolidinones and mannich bases of 4-amino-3-mercapto-5-pyridin-3’-yl-[1,2,4]-triazole. Ind J Chem 2007; 46(B): 352-6.
